Variable | Â | Univariate model | Multivariate model 1 | Multivariate model 2 |
---|---|---|---|---|
 |  | Odds ratio, 95% CI (P-value) | Odds ratio, 95% CI (P-value) | Odds ratio, 95% CI (P-value) |
Age (continuous) | Â | 1.01, (0.96; 1.06) 0.767 | Â | Â |
Age (<34 = 0, >34 = 1) | Â | 1.49, (0.75; 2.96) 0.258 | 2.20, (0.94; 5.15) 0.068 | 1.77, (0.83; 3.78) 0.142 |
Gender (male = 0, female = 1) | Â | 0.58, (0.24; 1.41) 0.227 | 0.65, (0.23; 1.85) 0.419 | Â |
WHO stage (1&2 = 0, 3&4 = 1) | Â | 0.94, (0.33; 2.71) 0.906 | 1.45, (0.44; 4.83) 0.543 | Â |
Baseline CD4 count cells/mm3 (>50 = 0, <50 = 1) | Â | 0.35, (0.14; 0.86) 0.022 | 0.38, (0.14; 1.07) 0.067 | 0.41, (0.16; 1.09) 0.075 |
Baseline viral load log copies/ml (<5 = 0, >5 = 1) | Â | 0.41, (0.20; 0.83) 0.014 | 0.55, (0.20; 1.49) 0.239 | 0.50, (0.23; 1.09) 0.081 |
Pre-HAART MHS score (continuous) | Â | 1.10 (1.05; 1.16) <0.001 | 1.10 (1.04; 1.16) <0.001 | 1.09 (1.04; 1.15) 0.001 |
Week 48 CD4 count cells/mm3 (<250 = 0, >250 = 1) | Â | 1.67, (0.83; 3.37) 0.151 | Â | Â |
Week 48 CD4 count cells/mm3 | <200 | 1 | Â | Â |
 | 200–350 | 5.18, (1.92; 13.96) 0.001 |  |  |
 | 350–500 | 2.39, (0.72; 7.91) 0.155 |  |  |
 | >500 | 2.52, (0.58; 10.88) 0.216 |  |  |
Week 48 viral load copies/ml (<50 = 0, >50 = 1) | Â | 1.30, (0.57; 2.94) 0.535 | Â | Â |
Week 48 viral load copies/ml | <50 | 1 | Â | Â |
 | 50–399 | 0.95, (0.33; 2.69) 0.919 |  |  |
 | 400–4999 | 2.05, (0.28; 15.14) 0.481 |  |  |
 | >5000 | 2.05, (0.49; 8.66) 0.327 |  |  |
Week 48 viral load log copies/ml (<1.69 = 0, >1.69 = 1) | Â | 1.30, (0.57; 2.94) 0.535 | Â | Â |
Week 48 viral load log copies/ml | <1.69 | 1 | Â | Â |
 | 1.69–2.59 | 0.88, (0.31; 2.47) 0.808 |  |  |
 | 2.60–3.69 | 2.05, (0.28; 15.14) 0.481 |  |  |
 | >3.69 | 2.74, (0.58; 12.85) 0.202 |  |  |
Δ CD4 count cells/mm3 |  | 0.999, (0.996; 1.002) 0.414 | 1.002, (0.998; 1.01) 0.389 |  |
Δ log viral load log copies/ml |  | 0.67, (0.44; 1.01) 0.054 | 0.74, (0.43; 1.28) 0.282 |  |